You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
奧賽康(002755.SZ):子公司新藥ASKC202片獲得臨牀試驗申請受理通知書
格隆匯 12-05 18:46

格隆匯12月5日丨奧賽康(002755.SZ)公佈,公司的全資子公司江蘇奧賽康藥業有限公司(以下簡稱"江蘇奧賽康")於近日收到國家藥品監督管理局(以下簡稱"藥監局")下發的 ASKC202 片新藥臨牀試驗申請《受理通知書》。

據悉,ASKC202 片是具有自主知識產權的 1 類新藥,是一種強效、高選擇性的口服小分子 c-MET 抑制劑。多種癌症中出現 MET 基因改變或蛋白異常表達現象,包括非小細胞肺癌、胃癌、肝細胞癌等。MET 通路異常激活引起 MET 基因擴增、蛋白過表達或基因突變,除了作為原發驅動致癌因素,MET 過量激活與其它靶向療法的耐藥機制相關,其中最主要的為 EGFR 抑制劑的旁路耐藥,5%-22%EGFR 抑制劑耐藥非小細胞肺癌患者出現 MET 基因擴增。靶向 c-MET 已成為腫瘤治療領域的研發熱點,國際上批准了兩款高選擇性 MET 抑制劑,分別是默克公司開發的 tepotinib 和諾華公司開發的 capmatinib,目前國內僅有和記黃埔的沃利替尼片於 2021 年 6 月獲批上市。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account